Gene Polymorphism at Codon 72 As a Response Predictor for Neoadjuvant Chemotherapy

Overview

Journal Breast Care (Basel)

Publisher Karger

Date 2024 May 20

PMID 38765899

Authors

Jussane Oliveira Vieira

Joao Bosco Pesquero

Afonso Celso Pinto Nazario

Affiliations

Soon will be listed here.

Abstract

Introduction: Breast cancer is the most prevalent cancer in women worldwide, and neoadjuvant chemotherapy is a favored method for achieving pathologic complete response (pCR). The gene is involved in inducing the response to chemotherapy drugs.

Objectives: The present study sought to correlate polymorphism variants at codon 72 with pCR to neoadjuvant chemotherapy.

Casuistry And Methods: The study was conducted in the state of Sergipe, in northeastern Brazil. A total of 206 patients with a histopathological diagnosis of breast cancer who underwent neoadjuvant chemotherapy from 2019 to 2022 were included. DNA samples were collected for the evaluation of polymorphism at codon 72. A prospective evaluation of the cases was conducted to verify the surgical pathologic response after chemotherapy; the Response Evaluation Criteria in Solid Tumors (RECIST) were used. The study was approved by the University of São Paulo Ethics and Research Committee.

Results: Of the 168 patients, 44.6% were Arg72Arg, 17.3% were Pro72Pro, and 38.0% were Arg72Pro; pCR was achieved in 21.4% of the patients; 10.1% had progressive disease, 13.7% had stable disease, and 54.2% had a partial pathologic response. The only predictor of pCR in multivariate regression was immunohistochemistry ( < 0.001). In the multivariate analysis, Arg72Pro and Pro72Pro increased the odds of the patient evolving with stable disease. This study was innovative in demonstrating a predictor of stable disease in response to neoadjuvant chemotherapy.

Conclusion: polymorphism at codon 72 is not a predictor of pCR, but it can be a predictor of stable disease.

Citing Articles

The role of multiparametric MRI in predicting lymphovascular invasion in breast cancer patients.

Wang J, Jing S, Yang Z, Tan W, Liu Y Future Oncol. 2024; 20(35):2747-2756.

PMID: 39268927 PMC: 11572066. DOI: 10.1080/14796694.2024.2396273.

References

Johnstone R, Ruefli A, Lowe S . Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108(2):153-64. DOI: 10.1016/s0092-8674(02)00625-6. View

Muller C, Schmidt G, Juhasz-Boss I, Jung L, Huwer S, Solomayer E . Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Arch Gynecol Obstet. 2021; 304(4):1065-1071. PMC: 8429372. DOI: 10.1007/s00404-021-06018-6. View

Basu S, Murphy M . Genetic Modifiers of the p53 Pathway. Cold Spring Harb Perspect Med. 2016; 6(4):a026302. PMC: 4817744. DOI: 10.1101/cshperspect.a026302. View

Basu S, Gnanapradeepan K, Barnoud T, Kung C, Tavecchio M, Scott J . Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α. Genes Dev. 2018; 32(3-4):230-243. PMC: 5859965. DOI: 10.1101/gad.309062.117. View

Haque W, Verma V, Hatch S, Klimberg V, Butler E, Teh B . Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018; 170(3):559-567. DOI: 10.1007/s10549-018-4801-3. View

Prete S, Caraglia M, Luce A, Montella L, Galizia G, Sperlongano P . Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. Oncol Lett. 2019; 18(4):3873-3879. PMC: 6732960. DOI: 10.3892/ol.2019.10729. View

Papadakis E, Dokianakis D, Spandidos D . p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun. 2000; 3(6):389-92. DOI: 10.1006/mcbr.2000.0241. View

Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo A, Fraser Symmans W . Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007; 25(19):2650-5. DOI: 10.1200/JCO.2006.08.2271. View

Darb-Esfahani S, Denkert C, Stenzinger A, Salat C, Sinn B, Schem C . Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget. 2016; 7(42):67686-67698. PMC: 5356512. DOI: 10.18632/oncotarget.11891. View

10.

Sharma S, Rathore S, Verma V, Kalyan M, Singh N, Irshad I . Molecular Subtypes As Emerging Predictors of Clinicopathological Response to Neoadjuvant Chemotherapy (NACT) in Locally Advanced Breast Cancer (LABC): A Single-Centre Experience in Western India. Cureus. 2022; 14(5):e25229. PMC: 9217662. DOI: 10.7759/cureus.25229. View

11.

Zhu Z, Shen H, Xu J, Fang Z, Wo G, Ma Y . GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells. Drug Resist Updat. 2023; 69:100974. DOI: 10.1016/j.drup.2023.100974. View

12.

Marin M, Jost C, Brooks L, Irwin M, ONions J, Tidy J . A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000; 25(1):47-54. DOI: 10.1038/75586. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Lundgren C, Bendahl P, Borg A, Ehinger A, Hegardt C, Larsson C . Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Res Treat. 2019; 178(2):459-467. PMC: 6797629. DOI: 10.1007/s10549-019-05378-7. View

15.

Dastjerdi M, Aboutorabi R, Eslami Farsani B . Association of TP53 gene codon 72 polymorphism with endometriosis risk in Isfahan. Iran J Reprod Med. 2014; 11(6):473-8. PMC: 3941319. View

16.

Szkandera J, Absenger G, Dandachi N, Regitnig P, Lax S, Stotz M . Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Mol Genet Genomics. 2012; 287(9):755-64. DOI: 10.1007/s00438-012-0715-7. View

17.

Al-Hilli Z, Boughey J . The timing of breast and axillary surgery after neoadjuvant chemotherapy for breast cancer. Chin Clin Oncol. 2016; 5(3):37. DOI: 10.21037/cco.2016.03.26. View

18.

Bonafe M, Salvioli S, Barbi C, Mishto M, Trapassi C, Gemelli C . p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. Biochem Biophys Res Commun. 2002; 299(4):539-41. DOI: 10.1016/s0006-291x(02)02691-8. View

19.

Xu K, Yin X, Zhou B, Zheng X, Wang H, Chen J . FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients. Cancer Lett. 2023; 562:216145. DOI: 10.1016/j.canlet.2023.216145. View

20.

von Minckwitz G, Untch M, Blohmer J, Costa S, Eidtmann H, Fasching P . Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15):1796-804. DOI: 10.1200/JCO.2011.38.8595. View